A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

After a screening period of up to 28 days prior to study drug administration, eligible participants will be residential for a single period of 5 days/4 nights in Part 1: single ascending dose, and 11 days/10 nights in Part 2 multiple ascending dose. Part 1 is composed of 6 parallel cohorts (cohorts 1.1 to 1.6) and up to 2 optional cohorts (cohorts 1.7 and 1.8) of 8 healthy adult male and female subjects in each cohort. If the data from cohorts 1.1 to 1.6 are not sufficient to characterize safety, tolerability and pharmacokinetics, up to 2 optional cohorts (cohorts 1.7 and 1.8) may be added. Part 2 is composed of 4 parallel cohorts (cohorts 2.1 to 2.4) and 1 optional cohort (cohort 2.5) of 12 healthy adult male and female subjects in each cohort and 1 cohort (cohort 2.6) of 12 healthy elderly male and female subjects. Dosing of the elderly cohort (cohort 2.6) will commence after having established the safety and tolerability of the corresponding dose tested in cohorts 2.1 to 2.5. If the data from cohorts 2.1 to 2.4 are not sufficient to characterize safety, tolerability and pharmacokinetics, 1 optional cohort (cohort 2.5) may be added.